IONS

72.70

4.33% 3.02

Handel nachbörslich: 72.70

Ionis Pharmaceuticals Inc (IONS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$69.68

Offen:

$70.68

24-Stunden-Volumen:

2.94M

Relative Volume:

1.33

Marktkapitalisierung:

$12.01B

Einnahmen:

$943.38M

Nettoeinkommen (Verlust:

$-380.99M

KGV:

-29.47

EPS:

-2.4667

Netto-Cashflow:

$-325.67M

1W Leistung:

+1.44%

1M Leistung:

-10.17%

6M Leistung:

+15.45%

1J Leistung:

+125.29%

1-Tages-Spanne:

$70.68

$73.61

1-Wochen-Bereich:

$68.90

$73.61

52-Wochen-Spanne:

$23.95

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Firmenname

Ionis Pharmaceuticals Inc

Sektor

Healthcare (1114)

Branche

Biotechnology (623)

Telefon

(760) 931-9200

Adresse

2855 GAZELLE COURT, CARLSBAD, CA

Mitarbeiter

1,402

Twitter

@ionispharma

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ALNY, ARGX, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IONS Ionis Pharmaceuticals Inc	72.70	11.51B	943.38M	-380.99M	-325.67M	-2.4667
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-10-08	Hochstufung	JP Morgan	Neutral → Overweight
2025-09-26	Hochstufung	Goldman	Sell → Neutral
2025-09-03	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2025-07-31	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-07-01	Hochstufung	Barclays	Equal Weight → Overweight
2025-04-07	Eingeleitet	H.C. Wainwright	Buy
2025-03-31	Eingeleitet	Redburn Atlantic	Neutral
2024-08-02	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-07-24	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-07-16	Fortgesetzt	Jefferies	Buy
2024-06-14	Hochstufung	Bernstein	Underperform → Mkt Perform
2024-04-10	Hochstufung	Wolfe Research	Peer Perform → Outperform
2024-01-02	Hochstufung	BofA Securities	Neutral → Buy
2023-10-23	Hochstufung	BofA Securities	Underperform → Neutral
2023-09-29	Eingeleitet	Raymond James	Strong Buy
2023-07-31	Hochstufung	Citigroup	Neutral → Buy
2023-06-07	Fortgesetzt	Piper Sandler	Overweight
2023-05-04	Hochstufung	Citigroup	Sell → Neutral
2023-03-21	Eingeleitet	Bernstein	Underperform
2022-12-21	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	Fortgesetzt	Morgan Stanley	Overweight
2022-07-18	Fortgesetzt	Oppenheimer	Outperform
2022-03-31	Fortgesetzt	Piper Sandler	Overweight
2022-03-01	Eingeleitet	Citigroup	Sell
2022-03-01	Eingeleitet	Guggenheim	Buy
2022-02-01	Herabstufung	BofA Securities	Buy → Underperform
2021-12-14	Hochstufung	William Blair	Mkt Perform → Outperform
2021-05-07	Hochstufung	UBS	Sell → Neutral
2021-03-01	Hochstufung	Barclays	Underweight → Equal Weight
2020-12-16	Eingeleitet	UBS	Sell
2020-12-15	Hochstufung	Cowen	Market Perform → Outperform
2020-09-14	Fortgesetzt	JP Morgan	Neutral
2020-09-02	Eingeleitet	The Benchmark Company	Hold
2020-06-01	Fortgesetzt	Oppenheimer	Outperform
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2019-12-13	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-11-07	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	Hochstufung	Bernstein	Mkt Perform → Outperform
2018-08-08	Bestätigt	Stifel	Hold
2018-08-07	Bestätigt	Stifel	Hold
2018-05-08	Herabstufung	Evercore ISI	Outperform → In-line
2017-10-06	Fortgesetzt	Goldman	Sell
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-08-09	Bestätigt	Stifel	Hold
2017-03-10	Herabstufung	Goldman	Neutral → Sell
2016-12-28	Bestätigt	BMO Capital Markets	Outperform
2016-12-27	Bestätigt	Leerink Partners	Mkt Perform

Alle ansehen

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

01:44 AM

Stifel raises Ionis Pharmaceuticals price target on drug pricing By Investing.com - Investing.com India

01:44 AM

12:35 PM

IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO - GuruFocus

12:35 PM

11:55 AM

Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat

11:55 AM

11:36 AM

IONS: HC Wainwright & Co. Raises Price Target to $120 | IONS Sto - GuruFocus

11:36 AM

11:17 AM

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright - MarketBeat

11:17 AM

10:43 AM

Wolfe Research reiterates Ionis stock rating on pricing strategy - Investing.com

10:43 AM

02:17 AM

Patterns Watch: Why is Ionis Pharmaceuticals Inc stock going upAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn

02:17 AM

Mar 24, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail

Mar 24, 2026

Aug Big Picture: Does Ionis Pharmaceuticals Inc outperform in volatile marketsSwing Trade & Weekly Chart Analysis and Guides - baoquankhu1.vn

Mar 24, 2026

When Insider Selling Is a Good Thing: 2 Stocks to Watch - Investing.com

Mar 24, 2026

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView

Mar 24, 2026

FDA accepts zilganersen application for Alexander disease review By Investing.com - Investing.com Canada

Mar 24, 2026

Ionis Pharmaceuticals (IONS) Gains FDA Priority Review for Zilga - GuruFocus

Mar 24, 2026

Mar 23, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $412,477.64 in Stock - MarketBeat

Mar 23, 2026

Ionis Pharma EVP Schneider sells $412k in shares By Investing.com - Investing.com South Africa

Mar 23, 2026

Ionis Pharma EVP Schneider sells $412k in shares - Investing.com

Mar 23, 2026

Ionis gains priority review for zilganersen for Alexander disease - MSN

Mar 23, 2026

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - BioSpace

Mar 23, 2026

FDA Prioritizes Review of Ionis Pharmaceuticals' Drug for Alexan - GuruFocus

Mar 23, 2026

Ionis Pharmaceuticals, Inc. recently announced that its New Drug Application (NDA) for Zilganersen, a new treatment developed for Alexander disease (AxD), has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA). - Bitget

Mar 23, 2026

FDA accepts zilganersen application for Alexander disease review - Investing.com

Mar 23, 2026

Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus

Mar 23, 2026

Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Mar 23, 2026

Mar 22, 2026

Ionis Board Shakeup And Valuation Gap Draw Investor Attention - Yahoo Finance

Mar 22, 2026

Mar 20, 2026

Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart

Mar 20, 2026

Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative (NASDAQ:IONS) - Seeking Alpha

Mar 20, 2026

IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill

Mar 20, 2026

Mar 19, 2026

Affiliate files Form 144 to sell shares — IONS (NASDAQ: IONS) - Stock Titan

Mar 19, 2026

Why Ionis Pharmaceuticals’ (IONS) 2026 catalyst pipeline supported Leerink’s higher target - MSN

Mar 19, 2026

Hudson Bay Capital Management LP Decreases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Mar 19, 2026